Bioventus Inc. (NYSE:BVS) CFO Mark Leonard Singleton Sells 3,875 Shares

Bioventus Inc. (NYSE:BVS) CFO Mark Leonard Singleton sold 3,875 shares of the business’s stock in a transaction that occurred on Friday, April 11th. The stock was sold at an average price of $7.57, for a total value of $29,333.75. Following the sale, the chief financial officer now directly owns 141,088 shares of the company’s stock, valued at $1,068,036.16. This represents a 2.67 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Mark Leonard Singleton also recently made the following trade(s):

• On Monday, March 24th, Mark Leonard Singleton sold 5,479 shares of Bioventus stock. The shares were sold at an average price of $9.79, for a total value of $53,639.41.
• On Tuesday, February 18th, Mark Leonard Singleton sold 6,498 shares of Bioventus stock. The shares were sold at an average price of $10.19, for a total value of $66,214.62.

Bioventus Stock Performance

Shares of Bioventus stock traded down $0.18 during trading hours on Tuesday, hitting $7.74. 429,619 shares of the company’s stock traded hands, compared to its average volume of 441,593. The stock has a market capitalization of $634.25 million, a price-to-earnings ratio of -12.69 and a beta of 0.92. Bioventus Inc. has a 12-month low of $3.90 and a 12-month high of $14.38. The company has a debt-to-equity ratio of 1.85, a current ratio of 1.41 and a quick ratio of 0.99. The company has a fifty day simple moving average of $9.52 and a 200-day simple moving average of $10.70.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on BVS shares. Canaccord Genuity Group reiterated a “buy” rating and issued a $15.00 target price on shares of Bioventus in a research note on Monday, March 17th. JPMorgan Chase & Co. upgraded shares of Bioventus from an “underweight” rating to a “neutral” rating and increased their price objective for the company from $12.00 to $13.00 in a research note on Tuesday, December 17th.

Institutional Trading of Bioventus

A number of large investors have recently added to or reduced their stakes in BVS. JPMorgan Chase & Co. grew its position in shares of Bioventus by 228.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 253,740 shares of the company’s stock valued at $3,032,000 after acquiring an additional 176,442 shares during the period. State Street Corp grew its holdings in Bioventus by 38.8% during the third quarter. State Street Corp now owns 676,501 shares of the company’s stock valued at $8,084,000 after purchasing an additional 189,216 shares during the period. Barclays PLC increased its position in Bioventus by 24.2% in the third quarter. Barclays PLC now owns 50,654 shares of the company’s stock worth $606,000 after buying an additional 9,854 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Bioventus by 7.5% in the third quarter. Geode Capital Management LLC now owns 940,496 shares of the company’s stock valued at $11,241,000 after buying an additional 65,374 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Bioventus by 11.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 435,344 shares of the company’s stock valued at $4,571,000 after buying an additional 45,182 shares during the last quarter. Hedge funds and other institutional investors own 62.94% of the company’s stock.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.